Area of research
Pulmonary and Respiratory Medicine · Oncology
Research interest
Research interests include HER2/EGFR in Cancer Research, Advanced Breast Cancer Therapies, Lung Cancer Treatments and Mutations, and Brain Metastases and Treatment.
Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a randomized phase 3 trial
Dual Strategies Based on Golgi Apparatus/Endoplasmic Reticulum Targeting and Anchoring for High-Efficiency siRNA Delivery and Tumor RNAi Therapy
Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): 4-year outcomes from a double-blind, randomised, phase 3 trial
Novel CDK2/4/6 inhibitor culmerciclib (TQB3616) plus fulvestrant in previously treated, HR-positive, HER2-negative advanced breast cancer: a randomized, double-blind, phase 3 trial
Pyrotinib in the first-line treatment of HER2-positive advanced breast cancer: Results from the PRETTY study.
Sacituzumab tirumotecan (SKB264/MK-2870) in patients (pts) with previously treated locally recurrent or metastatic triple-negative breast cancer (TNBC): Results from the phase III OptiTROP-Breast01 study.
RNA-binding protein GIGYF2 orchestrates hepatic insulin resistance through STAU1/PTEN-mediated disruption of the PI3K/AKT signaling cascade
Linarin Identified as a Bioactive Compound of Lycii Cortex Ameliorates Insulin Resistance and Inflammation Through the c‐<scp>FOS</scp>/<scp>ARG2</scp> Signaling Axis
Deciphering interleukin‐18 in diabetes and its complications: Biological features, mechanisms, and therapeutic perspectives
Role of PD‐1 in modulating IFN‐γ‐CXCL9/10‐CXCR3 signaling in breast cancer
A phase Ib study of PI3Kα inhibitor risovalisib mesylate in combination with fulvestrant in patients with <i>PIK3CA</i>-mutated, HR+/HER2- advanced breast cancer.
Pyrotinib plus docetaxel as first-line treatment for HER2-positive metastatic breast cancer: the PANDORA phase II trial
Efficacy, safety and pharmacokinetics of Unecritinib (TQ-B3101) for patients with ROS1 positive advanced non-small cell lung cancer: a Phase I/II Trial
ETNPPL modulates hyperinsulinemia‐induced insulin resistance through the SIK1/ROS‐mediated inactivation of the PI3K/AKT signaling pathway in hepatocytes
Real‐world treatment patterns and outcomes of pyrotinib‐based therapy in patients with <scp>HER2</scp>‐positive advanced breast cancer (<scp>PRETTY</scp>): A nationwide, prospective, observational study
Abstract P2-13-40: Treatment patterns and adverse events of pyrotinib-based therapy in HER2-positive breast cancer patients in China: Results from a multicenter, real-world study